Wire · opportunities
FDA-Cleared Alzheimer's Blood Test Marks a Shift Toward Earlier, Less Invasive Diagnosis
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 August 2026 · Fusion42 review
The FDA has cleared PrecivityAD2, a blood-based test for detecting amyloid plaques linked to Alzheimer's disease, enabling earlier and less invasive diagnosis that could enhance patient triage and access to emerging therapies.
This Wire brief sits within Fusion42's coverage of Digital Health, and 10 sources have reported it between 20 Aug 2026 and 24 Aug 2026.
◆ ◆ The Wire takeaway
You need to rethink diagnosis workflows as amyloid testing moves into routine blood draws, creating a new gateway to therapy and trials that bypasses costly scans. This clearance redefines who gets tested and when in dementia care.
◆ Coverage
10 sources · first reported 20 Aug 2026 · latest 24 Aug 2026
◆ Related on Wire
◆ Topics